Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity

PURPOSE: Axicabtagene ciloleucel (axi-cel) was approved by the Food and Drug Administration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the basis of durable remission rates of approximately 40% in a clinical trial population. Whether this efficacy, and the rates of toxicity, would...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Jacobson, Caron A., Hunter, Bradley D., Redd, Robert, Rodig, Scott J., Chen, Pei-Hsuan, Wright, Kyle, Lipschitz, Mikel, Ritz, Jerome, Kamihara, Yusuke, Armand, Philippe, Nikiforow, Sarah, Rogalski, Michael, Maakaron, Joseph, Jaglowski, Samantha, Maus, Marcela V., Chen, Yi-Bin, Abramson, Jeremy S., Kline, Justin, Budde, Elizabeth, Herrera, Alex, Mei, Matthew, Cohen, Jonathon B., Smith, Stephen D., Maloney, David G., Gopal, Ajay K., Frigault, Matthew J., Acharya, Utkarsh H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7499617/
https://ncbi.nlm.nih.gov/pubmed/32667831
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02103
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados